Most prostate cancer cases in patients who have been screened for prostate-specific antigen (PSA) fall into a kind of "gray zone," where it is extremely difficult to predict outcomes at the time of diagnosis. A new collaboration between Genomatix Software, the Uniformed Service University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine will pool their resources to come up with a better prognostic marker for prostate cancer. "Next Generation Sequencing opens a new dimension in biomarker research and will allow a finer-grained, unbiased look at some of the genomic mechanisms behind prostate disease, thus providing the opportunity for the discovery of new prognostic biomarkers, some of which also may be targets for therapeutic intervention and treatment monitoring." Thomas Werner, founder of Genomatix Software, said in a release. Genomatix release | Item